Tests a modified cancer-killing virus in people with early skin melanoma
Tests RP1, a modified cancer-targeting virus, in adults with primary melanoma.
Key facts
- Who runs it
- Yana Najjar
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 25 people, planned
- Started
- 7 Mar 2024
- Expected to end
- 31 Mar 2029
- Type of study
- Interventional
- Treatments tested
- Vusolimogene oderparepvec (RP1)
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a thick primary melanoma (pT3b, T4a or T4b) that still has visible tumor or a positive margin after biopsy. They would receive RP1 injected into the tumor.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Melanoma of stage pT3b, T4a or T4b on biopsy, with visible leftover tumor or a positive deep or lateral margin. Uveal melanoma is not included.
- Earlier treatment
- Must not have had oncolytic virus therapy before. No investigational drug or device within 4 weeks and no live vaccine within 30 days before the first dose.
Main reasons for not taking part
- Prior oncolytic virus therapy
- Active hepatitis B or C, or HIV infection
- Active herpes infection or past serious complications of HSV-1 infection
- Solid organ transplant recipient
- Tumor near critical structures such as the carotid artery or portal vein
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Be willing and able to provide written informed consent for the trial
- Be ≥ 18 years of age on day of signing informed consent
- Have a diagnosis of pT3b, T4a or T4b melanoma on biopsy. Patients must have grossly visible residual tumor, or a positive deep or lateral margin on initial biopsy. Patients with uveal melanoma are not eligible
- Females of childbearing potential must have a negative beta-human chorionic gonadotropin (β-hCG) test with a minimum sensitivity of 25 IU/L or equivalent units of β-hCG during screening, before the first dose, and a negative urine pregnancy test on days of treatment (Day 1, 15 and 21). For serum and urine pregnancy tests and instructions (see Section 12.2)
- Female patients of reproductive potential must agree to avoid becoming pregnant and adhere to a highly effective contraception method until 90 days after last dose of RP1 alone. For a definition of highly effective contraceptive methods and instructions of patients and partners (see Section 12.2)
- Male patients of reproductive potential must agree to avoid impregnating a partner and adhere to a highly effective contraception method until 90 days after last dose of RP1 study agent and refrain from donating sperm during this period. For a definition of highly effective contraceptive methods and instructions of patients and partners (see Section 12.2); Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
- Demonstrate adequate organ function. All screening labs should be performed within 30 days of treatment initiation. Baseline labs may be used as screening labs
Who cannot take part
- Prior treatment with an oncolytic virus therapy
- Had systemic infection requiring IV antibiotics or other serious infection within 14 days prior to dosing
- Have active significant herpetic infections or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis)
- Conditions requiring treatment with immunosuppressive doses (> 10 mg daily prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days after enrollment. For the definition of replacement therapy (Section 11.0 Supportive Care and Management of Adverse Reactions/Events)
- Major surgery ≤ 1 week prior to starting study drug. Note: Patients who undergo major surgery must adequately recover prior to starting study treatment
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within four weeks prior to the first dose of study treatment
- Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacille Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed, however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed; Note: Available COVID-19 vaccines do not contain live virus
- Is a solid organ transplant recipient
- Has a concurrent malignancy requiring active systemic therapy or ongoing radiation
- Has acute or chronic active hepatitis B and C virus infection or known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) (defined as HCV RNA [qualitative]) or HIV infection; Note: No testing for Hepatitis B, Hepatitis C, or HIV is required unless mandated by local health authority or clinically indicated
- History of documented allergic reactions or acute hypersensitivity reactions attributed to RP1 or any of its excipients
- Has serious or uncontrolled medical disorders
- Has known psychiatric, alcohol abuse, or substance abuse disorders that would interfere with cooperating with the requirements of the study
- Patients with tumors that are located near critical structures, such as the carotid artery or portal vein, or scalp lesions presenting with moderate to extensive bone erosion and tumors that may have invaded the heart, great vessels, or other critical structures will not be eligible because these area should not be injected. Injection through an ulcerated area of a lesion should be avoided
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate, in the opinion of the treating Investigator
- Is a person deprived of their liberty by a judicial or administrative decision, or an adult person subject to a legal protection measure
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Amy Rose, RN, BSNTaking people
About the trial
What the trial wants to find out
This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor cell lysis and the release of virus particles which infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune system is activated by the released tumor-associated antigens (TAAs) from the tumor cells creating an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.
The group in the trial
- Vusolimogene oderparepvec (RP1)Treatment being tested
Patients will receive 3 doses of RP1 (1.0 mL/injection; 10e6 PFU/mL for the first dose, and 10e7 mL for the subsequent 2 doses). The drug will be injected into the skin at the tumor biopsy site at baseline (day 1), day 15, and day 21, 4-5 weeks prior to SOC WLE and SLNB. Definitive surgery will occur up to 28-35 (± 2 days) days from first injection, to avoid treatment delay.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
- Plain-language title
- Tests a modified cancer-killing virus in people with early skin melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 April 2026